← Back to all trials
Completed
NCT04666610
A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
Conditions: Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Sex: All
Ages: 2 Years – 25 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 153
Sponsor: UCB Biopharma SRL
Location: N01269 115 Birmingham Alabama
Summary
The purpose of the study is to test the efficacy, safety and tolerability of brivaracetam monotherapy in study participants 2 to 25 years of age inclusive with childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE).
Eligibility Criteria
Inclusion Criteria:
* Study participant is 2 to 25 years of age inclusive, at the time of signing the informed consent. No study participants from 2 to \
Source: ClinicalTrials.gov (NCT04666610). StuddyBuddy aggregates publicly available trial information.
